Safety, Efficacy and a Simple Model to Predict Response of BNT162b2 mRNA

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 06 Apr 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Dec 2021 Results investigating T-cell response determined by interferon gamma (IFNy) secretion in patients with CLL following BNT162b mRNA Covid-19 vaccine, in comparison with serologic response presented at the 63rd American Society of Hematology Annual Meeting and Exposition
03 Dec 2021 Results (n=172) evaluating the antibody response to a third BNT162b2 mRNA vaccine in patients with CLL/small lymphocytic lymphoma, published in the Blood
04 May 2021 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com